Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
Annals of Rheumatic Diseases Feb 12, 2022
Researchers examined how disease modifying antirheumatic drugs (DMARD) combination and monotherapy are associated with an immune response to an inactivated SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA).
Seroconversion (SC) of anti-SARS-CoV-2 immunoglobulin G (IgG) and neutralizing antibodies (NAb) induced by the inactivated vaccine (CoronaVac) were analyzed in this phase 4 prospective study of patients with RA in comparison to controls (CG).
Moderate but lower SC (61.8% vs 94.2%) and NAb positivity (45% vs 78.6%) were recorded in patients with RA in comparison to CG after full vaccination.
Immunogenicity was adversely affected by nearly all DMARD combinations, whereas this response was also hampered by a more restricted number of drugs (methotrexate/tofacitinib/abatacept/tocilizumab) as monotherapy.
Considering these findings, researchers emphasize the necessity for a broader approach, not limited to specific drugs, to improve vaccine response for this population.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries